selection should consider presence of cardiovascular disease, heart failure, or chronic kidney disease DPP-4 inhibitors (such as sitagliptin or linagliptin) oral agents with a different mechanism Insulin therapy particularly if glycaemic control is inadequate with oral agents Pioglitazone may be appropriate in selected patients without heart failure Sulfonylureas (such as gliclazide) though associated with hypoglycaemia and weight gain Your diabetes specialist or GP will conduct a comprehensive review of your treatment plan, considering factors such as HbA1c targets, cardiovascular risk profile, renal function, and personal preferences
Intramuscular injection might occur if the needle is too long for the patient's body habitus or if the injection technique is incorrect
In addition to this, ShedRx also offers $100 off to our readers
They cost between 30 and 80 dollars and eliminate the risk entirely
While Wegovy is already a higher-dose formulation of semaglutide (its maximum prescribed dose is 2.4 milligrams, compared to the maximum one milligram dose for Ozempic), the company is banking that the drugs effectiveness hasnt yet reached its ceiling
23 Ultimately, termination of GLP-1 RA treatment due to GI AEs remains an option for patients who exhibit severe symptoms
